ClinicalTrials.gg
RecruitingNCT05907317SafeBoosC-IIIvUpdated Apr 25, 2025

Safeguarding the Brain of Our Smallest Children-IIIv (SafeBoosC-IIIv)

A Phase 3 interventional study of Cerebral oximetry monitoring device and Usual care in Hypoxia and Infant, Newborn, Diseases, sponsored by Copenhagen Trial Unit, Center for Clinical Intervention Research. Recruiting at 1 site in Spain. Open to participants aged 0 Days to 28 Days. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by Copenhagen Trial Unit, Center for Clinical Intervention Research · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,610
Allocation
Randomized
Ages
0 Days to 28 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Hypoxia with a site in Spain — 11 open to participants now, 11 under way, 5 of them phase 3. Hypoxia · Spain.

Planned enrollment
Largest of 25
1,610 · median 60
Started
2025
with 2 others
Phase 3
5 of 31
5 open now
Primary completion
2029-02
later than 10 of 10 live
Registered
18th of 31
by date
Lead sponsor
1 of 31
Copenhagen Trial Unit, Center for Clinical Intervention Research

Among the 31 studies in Hypoxia with a site in Spain, this one has the largest planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 3, reaches primary completion later than 10 of the 10 other live ones, and was the 18th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

11 of the 31 studies in Hypoxia with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 0 Days to 28 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Hypoxia with a site in Spain, or all of them as a file.
02

Study summary

The objective of the SafeBoosC-IIIv trial is to assess benefits and harms of cerebral oximetry in newborns receiving invasive mechanical ventilation. The hypothesis is that:

i. Cerebral oximetry added to usual care versus usual care alone in newborns receiving invasive mechanical ventilation will increase the number of hospital-free days within 90 days of randomisation.

ii. The intervention will decrease a composite outcome of death or moderate to severe neurodevelopmental disability and/or increase the mean PARCA-R non-verbal cognitive score at two years of corrected age.

Read the detailed description

SafeBoosC-IIIv will be an investigator-initiated, multinational, randomised, pragmatic phase III clinical trial. The trial will be conducted in two steps. In step one, 1,610 newborns will be randomised, and the outcomes will be assessed 90 days after randomisation. Funding has been obtained for step one. If further funding is obtained, we will continue to include newborns until a total of 3,000 newborns are randomised and then follow them up at two years of corrected age (step two).

03

Conditions studied

  • Hypoxia
  • Infant, Newborn, Diseases

Keywords

  • Near-infrared spectroscopy
  • Randomised clinical trial
  • Mechanical ventilation
04

Who can participate

Ages eligible
0 Days to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age more than or equal to 28+0
  • Postnatal age less than 28 days
  • Expected to receive invasive mechanical ventilation (intubation) for at least 24 hours, as judged by the physician intending to randomise
  • Parental unless the centre has chosen to use 'opt-out' or deferred consent as consent method
  • A cerebral oximeter available so monitoring can be started within six hours after initiation of invasive mechanical ventilation

Exclusion criteria

Exclusion Criteria:

  • Suspicion of or confirmed brain injury or disorder (e.g. severe hypoxic-ischemic encephalopathy, intraventricular haemorrhage grade 3 or 4, cerebral malformation, genetic or metabolic disease)
  • Suspicion or diagnosis of congenital heart malformations likely to require surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
1,610 participants (estimated)

Study arms

  • Experimental
    Cerebral oximetry + usual care

    Device: Cerebral oximetry monitoring device · Other: Usual care

  • Other
    Usual care

    The control group will receive mechanical ventilation without access to cerebral oximetry and the SafeBoosC treatment guideline. If the newborn is cared for outside the neonatal unit at any time, e.g. during surgery, cerebral oximetry may or may not be used, as decided by the responsible physician there

    Other: Usual care

Interventions

  • DeviceCerebral oximetry monitoring device

    Participants in the experimental group will be monitored with cerebral oximetry, if possible before or, as soon as possible and within six hours after initiation of invasive mechanical ventilation. Cerebral oximetry will be continued until 1) the cardio-pulmonary function has been stabilised as indicated by the need for respiratory and circulatory support and evaluated by the responsible physician, 2) extubation, 3) until 28 days after birth, or 4) until death. Randomisation will only direct the use of cerebral oximetry during the first invasive mechanical ventilation episode. Cerebral oximetry will be used to minimise cerebral hypoxia by modifying clinical care according to the SafeBoosC treatment guideline and monitoring as usual.

  • OtherUsual care

    Treatment as usual

06

What researchers measure

Primary outcomes

  1. Hospital-free days within 90 days of randomisation

    Primary outcome for step one

    Time frame: 90 days

  2. A composite of death from any cause or moderate to severe neurodevelopmental disability

    Co-primary outcome for step two A composite of death from any cause or moderate to severe neurodevelopmental disability at two years of corrected age. Moderate to severe neurodevelopmental disability will be defined as one or more of the following 1. cerebral palsy with Global Motor Function Classification System level 2 or higher; 2. a Parent Report of Children's Abilities-Revised (PARCA-R) non-verbal cognitive function score (range 0-34, higher score means better outcome) below -2 standard deviations (SD); 3. hearing loss corrected with aids or worse; or 4. vision impairment defined as moderately reduced vision of one eye, or only being able to perceive light or light reflecting objects; or blind in one eye with good vision in the contralateral eye.

    Time frame: 2 years

  3. Parental questionnaires

    Co-primary outcome for step two: Parental questionnaires completed between 18-30 months' corrected age as well as available data from at least 12 months' corrected age from health care records, including standardised neurodevelopmental assessments, will be used to assess mortality and neurodevelopment. • Non-verbal cognitive score of Parent Report of Children's Abilities-Revised (PARCA-R), a parental questionnaire, at two years of corrected age (range 0-34, higher score means better outcome).

    Time frame: 18-30 months

Secondary outcomes

  1. Proportion of participants with a serious adverse event

    Secondary outcome for step one: Proportion of participants with one or more Serious Adverse Events within the 90 days of randomization, i.e. one or more of the following: Death from any cause Bronchopulmonary dysplasia (BPD) Any brain injury diagnosed by imaging Seizures treated with antiepileptic medicine Haemodynamic insufficiency that needs cardiovascular support Spontaneous bowel perforation or necrotising enterocolitis (NEC) Bells grade 2 or more Nosocomial infection Extra Corporal Membrane Oxygenation (ECMO) Renal replacement therapy

    Time frame: 90 days

  2. Invasive mechanical ventilation-free days within 90 days of randomisation

    Secondary outcome for step one

    Time frame: 90 days

Other outcomes

  1. Late onset sepsis

    Exploratory outcome for step one

    Time frame: 90 days

  2. Invasive mechanical ventilation-related infection

    Exploratory outcome for step one

    Time frame: 90 days

  3. Cerebral palsy

    Exploratory outcome for step two: defined as Global Motor Function Classification System level 2 or above, at two years of corrected age.

    Time frame: 2 years

  4. Sensory deficit

    exploratory outcome for step two: defined as any degree of vision or hearing impairment, at two years of corrected age.

    Time frame: 2 years

  5. All-cause mortality

    Exploratory outcome for step two: Mortality at two years of corrected age.

    Time frame: 2 years

  6. Use of daily medication

    Exploratory outcome for step two: Use of medication during the last two months, at two years of corrected age.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Vestager ML, Hansen ML, Rasmussen MI, Hahn GH, Hyttel-Sorensen S, Pellicer A, Heuchan AM, Hagmann C, Dempsey E, Dimitriou G, Pichler G, Naulaers G, Fuchs H, Tkaczyk J, Mintzer J, Fumagalli M, Nesargi S, Fredly S, Szczapa T, Gluud C, Jakobsen JC, Greisen G. The effects of cerebral oximetry in mechanically ventilated newborns: a protocol for the SafeBoosC-IIIv randomised clinical trial. Trials. 2023 Oct 28;24(1):696. doi: 10.1186/s13063-023-07699-x. PubMed 37898759 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Feb 2029, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2023
First posted
Jun 18, 2023
StartActual
Apr 11, 2025
Primary completionEst.
Feb 1, 2029
CompletionEst.
Feb 1, 2029
Last update
Apr 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05907317
Lead sponsor
Copenhagen Trial Unit, Center for Clinical Intervention Research
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Apr 11, 2025
Primary completion
Feb 1, 2029 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Apr 25, 2025

Study contacts

Caroline Kamp, PhD
Contact
caroline.kamp@ctu.dk
+45 20 32 41 08
Johanne Juul Petersen
Contact
johanne.juul.petersen@ctu.dk
+45 28 93 30 35

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion